Loading, please wait...
| PARKING REQUEST FORM » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Wednesday, November 17, 2021
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 304
|
ARB 305
|
ARB 354
|
ARB 336
|
|
Link to Teams Meeting
|
||||
|
SESSION 1
1:00 – 1:45
|
Mikaela McCabe, Pharm.D.
Monoclonal Antibodies in Bacterial Infections
|
Brooke Jacobson, Pharm.D.
Just Say NO to HFrEF: The Utilization of Medications that Augment the Nitric Oxide Pathway in Patients with Heart Failure
|
Nikolas Dotolo, Pharm.D.
Non-Opioid Pain Control in Pediatric Sickle Cell Pain Crisis
|
Kathryn Storm, Pharm.D.
Management of Opioids in Chronic
Noncancer Pain
|
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 2
1:55 – 2:40
|
John Love, Pharm.D.
Prophylactic Anticoagulation in Patients with COVID-19
|
Conner McClain, Pharm.D.
Adjunctive Lipid Lowering Therapies
|
Rachel Mehringer, Pharm.D.
Three Drug versus Four Drug Regimens for Multiple Myeloma in Newly Diagnosed Transplant-eligible Patients
|
Nicole Short, Pharm.D.
A Closer Look at Episodic Migraine Prevention
|
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 3
2:50 – 3:40
|
William Miller, Pharm.D.
Updates and Controversies in C. difficile Treatment
|
Mark Herrington, Pharm.D.
Anticoagulation use in TAVR Patients with Atrial Fibrillation
|
Hansa Mreyoud, Pharm.D.
Letermovir for Cytomegalovirus (CMV) Prevention in Solid Organ Transplant Patients
|
Naomi Bailey, Pharm.D.
Aducanumab: A New Agent for the Treatment of Alzheimer’s Disease
|
Please join us for the second Resident Seminar session of the 2021-2022 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in classrooms in the Academic & Research Building (ARB) on the third floor (see classroom numbers above), as well as virtually (see Teams links above).
Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned for this Resident Seminar is 2.25 contact hours. Participants must complete an evaluation (see link above) to receive credit.
Click here for a printable copy of the schedule
REGISTRATION: To register for the LIVE Resident Seminar presentations, click here>>>. There is no need to register for the virtual presentations. Please use the links within the table above to connect to the VIRTUAL presentations. Special note, this event has multiple concurrent sessions.
Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual attendance is limitless.
Registration is free but is required in advance for the LIVE presentations. Due to limited space, only those participants who register for the LIVE session before 5:00 PM on Friday, November 12, 2021 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired LIVE sessions. Then, complete the Parking Request Form using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Participants attending the LIVE (on-campus) sessions will be provided paper copies of handouts within the classrooms. Virtual attendees can access the handouts in the conversation feature within Teams. Copies of PowerPoint slides are not provided.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy in St. Louis is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close November 24, 2021 at 11:59 PM (CST).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Nov 17, 2021 01:00 PM - 03:40 PM
Fee
$0.00
CE Hours
9.00
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
This session will review the background on monoclonal antibodies (mAbs) used for infectious diseases and their differing mechanisms of action. This session will also review the literature pertaining to newly approved mAbs and mAbs that are currently in clinical trials to look at the data surrounding some upcoming therapies for prevention/treatment of bacterial infections.
Objectives
- Describe mechanisms of monoclonal antibodies that target bacteria
- Identify current and new monoclonal antibodies for the treatment and prevention of bacterial infections
Speaker(s)/Author(s)
|
Mikaela McCabe, Pharm.D. |
Activity Number
0033-0000-21-048-L01-P
Date:
11/17/21
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 304 and Virtually
This continuing education seminar will examine the role of medications that augment the nitric oxide pathway in patients with heart failure with reduced ejection fraction. The presentation will begin by describing the background, etiology, and prevalence of heart failure followed by the pathophysiology. The pathophysiology in this presentation will specifically cover how the nitric oxide pathway is altered in patients with heart failure. Current guideline recommendations for optimizing heart failure medications will be reviewed. The presentation will then look at literature available for the nitric oxide augmenting agents. The trials that study the effectiveness of hydralazine/isosorbide (V-HeFT trials and the A-HeFT trial) will be reviewed and analyzed as well as the VICTORIA trial. The VICTORIA trial evaluates the efficacy of the newest agent in this drug class- vericiguat. The presentation will conclude with an evaluation of how these agents should be used in current practice. A treatment algorithm will be included to guide the decision on who should receive these agents. Evaluation of audience comprehension will be assessed throughout the presentation with multiple-choice questions.
Objectives
- Explain the dysregulation of the nitric oxide pathway that occurs in heart failure
- Describe vericiguat's mechanism of action and pertinent drug properties
- Select an appropriate patient with heart failure that would benefit from hydralazine/isosorbide or vericiguat
Speaker(s)/Author(s)
|
Brooke Jacobson, Pharm.D. |
Activity Number
0033-0000-21-055-L01-P
Date:
11/17/21
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 305 and Virtually
This continuing pharmacy education lecture will focus on non-opioid multi-modal analgesia in the setting of pediatric sickle cell disease pain crises. The psychophysiology of sickle cell disease pain crises will be explored, in addition to American Society of Hematology (ASH) medication recommendations for management of acute pain. In addition, literature for support of ASH recommendations and St. Louis Children's Hospital clinical practice will be reviewed. By the end of the presentation, the audience will be able to create a patient specific adjunct non-opioid pain regimen for patients presenting in sickle cell pain crises.
Objectives
- Describe the pathophysiology of pediatric sickle cell disease (SCD) pain crisis
- Compare and contrast non-opioid pain medications for sickle cell pain crisis management
- Select an adjunct non-opioid pain reliever for acute sickle cell pain based on patient specific factors
Speaker(s)/Author(s)
|
Nikolas Dotolo, Pharm.D. |
Activity Number
0033-0000-21-059-L01-P
Date:
11/17/21
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
354 and Virtually
In the face of an opioid epidemic, the CDC released guidelines on the appropriate prescribing of opioids in chronic pain (2016). Following, there was a sharp change in prescribing habits including avoiding, deprescribing, and/or discontinuing opioid therapy. This led to a new set of consequences for the patients who were left with chronic, uncontrolled pain. Given the dichotomy of approaches (overuse of opioids to potentially underutilization of opioids), prescribers and practitioners are left with unclear guidance from institutional and governing bodies in the setting of social focus. This presentation aims to address the considerations and appropriate management of opioids in chronic non-cancer pain. The presentation will review data available on long-term effects of opioids, considerations for prescribing and monitoring, and explore patient scenarios in which opioids may or may-not be appropriate for chronic non-cancer pain.
Objectives
- Discuss the implications of forced or fast opioid tapers on patient outcomes
- Discuss risk mitigation strategies for patients on long-term opioids
- Identify the risks and benefits of chronic opioid use
Speaker(s)/Author(s)
|
Kathryn Storm, Pharm.D. |
Activity Number
0033-0000-21-051-L01-P
Date:
11/17/21
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 355 and Virtually
Current guidelines recommend providing prophylactic anticoagulation to all patients hospitalized with COVID-19. These guidelines do not make recommendations for dosages other than prophylactic dosages due to a lack of data at the time of publication to make a recommendation either for or against higher dosages. This presentation will explore evidence evaluating different regimens for prophylactic anticoagulation in hospitalized patients with COVID-19, including postdischarge and special situations.
Speaker(s)/Author(s)
|
John Love, Pharm.D. |
Activity Number
0033-0000-21-053-L01-P
Date:
11/17/21
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 304 and Virtually
This program will review recent guideline updates regarding the treatment of C. difficile and will include an in-depth literature analysis of the studies that influenced these guidelines. Discrepancies between the 2021 IDSA/SHEA and ACG guidelines will be addressed, with emphasis on fidaxomicin versus vancomycin in patients with initial or recurrent C. difficile infection. Additionally, this presentation will discuss the place in therapy and cost-effectiveness of new agents used in the prevention or treatment of C. difficile infection.
Objectives
- Describe new treatment recommendations in the “Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults"
- Critique recent studies influencing C. difficile treatment recommendations
Speaker(s)/Author(s)
|
William Miller, Pharm.D. |
Activity Number
0033-0000-21-057-L01-P
Date:
11/17/21
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 304 and Virtually
Transcatheter aortic valve replacement (TAVR) is becoming more common and is often utlized in patients with aortic valve disease, even in those with low surgical risk. Approximately 50% of patients undergoing TAVR will have pre-exisiting Atrial Fibrillation (AF) or new onset post- procedural AF that requires treatment with an oral anticoagulant. Vitamin K Antagoinsts (VKA) have been the mainstay of therapy in TAVR patients with AF due to lack of published clinical data. More recently, clinical and real world data trials have been conducted comparing VKA to oral DOAC therapy in TAVR patients with AF given the increase in use of DOACs because of improved safey and efficacy and lack of monitoring. Data suggests similar efficacy and improved safety of DOACs over VKA which has impacted recent guidelines for anticoagluation in AF patients undergoing TAVR. At the conclusion of this seminar, pharmacists should understand the impact of valvular heart disease on patient outcomes, analyze current practice guidelines related to antithrombotic therapy in AF and TAVR, identify appropriate antithrombotic regimens for patients with AF undergoing TAVR, and apply guideline recommendations to formulate a treatment plan for appropriate AF patients undergoing TAVR.
Objectives
- Describe the impact of valvular heart disease on patient outcomes
- Define current practice guidelines related to antithrombotic therapy in AF and TAVR
- Identify appropriate antithrombotic regimens for patients with AF undergoing TAVR
- Explain how guideline recommendations inform the treatment plan for appropriate patients with AF undergoing TAVR
Speaker(s)/Author(s)
|
Mark Herrington, Pharm.D. |
Activity Number
0033-0000-21-058-L01-P
Date:
11/17/21
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 305 and Virtually
This CE program will provide a brief background regarding the standard of therapy for lipid lowering therapies in secondary hypercholesterolemia. Furthermore, current guideline recommendations will be discussed surrounding the addition of adjunctive lipid lowering treatments for patients on maximally tolerated standard of care and not at goal. Current and future adjunctive lipid lowering agents will then be discussed in detail. Lastly, recommendations will be made regarding these adjunctive therapies may be most beneficial. The overall goal of this presentation is to provide the audience with a better understanding of the available adjunctive lipid lowering therapies and how they may be used in practice.
Speaker(s)/Author(s)
|
Conner McClain, Pharm.D. |
Activity Number
0033-0000-21-054-L01-P
Date:
11/17/21
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 305 and Virtually
This continuing education seminar will provide a brief overview of multiple myeloma and commonly used agents for initial treatment of multiple myeloma. The presentation will then examine historical treatment of multiple myeloma, including primary literature and current guideline directed standard of care regimens. The presentation will then evaluate the pros and cons of four drug regimens for induction therapy in newly diagnosed, transplant eligible multiple myeloma patients. The continuing education will continue with an evaluation of recent primary literature comparing three drug induction regimens to four drug induction regimens for transplant eligible patients. The presentation will conclude by summarizing available data, and discussing the effect that these studies have had on clinical practice, as well as presenting unanswered questions and further areas of study. Evaluation of the audience comprehension will be assessed throughout the presentation in the form of multiple choice questions.
Objectives
- Describe the significance of of high-risk cytogenetics in determining multiple myeloma treatment
- Evaluate the impact of anti-CD38 monoclonal antibodies for the treatment of multiple myeloma
- Identify appropriate initial three and four drug treatment regimens for transplant candidates
Speaker(s)/Author(s)
|
Rachel Mehringer, Pharm.D. |
Activity Number
0033-0000-21-049-L01-P
Date:
11/17/21
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 354 and Virtually
This presentation will begin with an introduction to the characteristics of episodic migraine followed by an explanation of the mechanism of calcitonin gene-related peptide (CGRP) antagonists. An overview of current American Academy of Neurology recommendations and the European Headache Federation guidance on CGRP antagonists for episodic migraine prevention will be discussed. A literature review over the critical trials of injectable CGRP antagonists along with a trial of the first-line agent, topiramate will be presented. The findings of these trials will be compared and contrasted in order to help define the role and place in therapy for CGRP antagonists.
Objectives
- Differentiate episodic migraine from other types of migraine conditions
- Describe the mechanism of calcitonin gene-related peptide (CGRP) antagonists in the prevention of migraine
- Summarize the role of injectable GCRP antagonists in the prevention of episodic migraine
Speaker(s)/Author(s)
|
Nicole Short, Pharm.D. |
Activity Number
0033-0000-21-050-L01-P
Date:
11/17/21
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 355 and Virtually
This CE presentation will provide background of cytomegalovirus, current prevention strategies, and problems associated with current strategies with a focus on solid organ transplant patients. A brief overview of letermovir data in hematopoetic stem cell transplant patients will be reviewed prior to an in depth literature review of current data in solid organ transplant patients. By the end of this presentation pharmacists will be aware of the problems and considerations for use of letermovir in solid organ transplant patients. Pharmacists will be able to identify potential scenarios for letermovir use as well as its potential place in therapy in the future.
Objectives
- Identify solid organ transplant patients at the highest risk of a CMV infection
- Describe problems associated with current prevention strategies
- Evaluate appropriate use of letermovir in solid organ transplant patients, based on the currently available data
Speaker(s)/Author(s)
|
Hansa Mreyoud, Pharm.D. |
Activity Number
0033-0000-21-056-L01-P
Date:
11/17/21
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 354 and Virtually
Aducanumab is a new agent approved under the accelerated pathway by the FDA. With currently available medications only targeting symptoms of Alzheimer’s disease, aducanumab provides a novel mechanism of action in targeting the underlying pathology of the disease. Given the results from the trials using aducanumab, the medication has received extensive publicity. This presentation will review the data from those two trials, as well as, discuss some of the concerns with the medication’s approval and the clinical application.
Objectives
- Describe aducanumab’s mechanism of action and its role in the pathophysiology of Alzheimer’s disease
- Compare data obtained in the EMERGE and ENGAGE trials
- Discuss the rational behind the FDA’s approval of aducanumab
Speaker(s)/Author(s)
|
Naomi Bailey, Pharm.D. |
Activity Number
0033-0000-21-052-L01-P
Date:
11/17/21
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 355 and Virtually
